Isocitrate Dehydrogenase 2 Inhibitor Drug Class List

Drugs in Drug Class: Isocitrate Dehydrogenase 2 Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	12,433,895
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	9,579,324			Y
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-001	Aug 6, 2024		RX	Yes	No	10,172,864		Y	Y
Servier	VORANIGO	vorasidenib	TABLET;ORAL	218784-002	Aug 6, 2024		RX	Yes	Yes	10,172,864		Y	Y

Last updated: July 13, 2026

Isocitrate Dehydrogenase 2 (IDH2) Inhibitor Market Dynamics and Patent Landscape: What Patents Protect the Key Drugs, When Do They Expire, and Where Does Generic Risk Concentrate?

Which IDH2 inhibitors dominate the market and revenue exposure?

Core marketed IDH2 inhibitors:

• Enasidenib (Idhifa, Celgene/Bristol Myers Squibb) – primary long-running commercial anchor in IDH2.
• Olutasidenib (Rezlidhia, Blueprint Medicines) – newer launch with ramp exposure tied to FLT3 mutation negative and AML subpopulations in practice.
• Vorasidenib (Voranigo, Servier/Agios) is an IDH1/IDH2 dual inhibitor marketed for IDH-mutant glioma, but it is not IDH2-only for patent positioning.

Commercial and competitive dynamics (high level):

• IDH2 sits in a narrow, biomarker-defined oncology niche. Uptake depends on sequencing with chemotherapy, transplant eligibility, and mutation testing penetration (IDH2 R140Q most relevant for enasidenib/olutasidenib clinical programs).
• Market share shifts between enasidenib and olutasidenib hinge on expected response durability, tolerability, and local practice patterns in relapsed/refractory (R/R) AML and line-of-therapy access.

What patents protect enasidenib (Idhifa) and how strong is the estate?

Drug: Enasidenib (IDH2 inhibitor; oral small molecule)
Primary patent estate focus:

• Compound claims (IDH2 inhibitory small molecules)
• Formulation and solid-state polymorphs
• Crystalline forms, solvates, and manufacturing-related process claims
• Method-of-use claims for AML treatment in patient-defined molecular contexts

Estate strength indicators that usually control enforcement leverage:

• Breadth of composition-of-matter claims across structural variants
• Presence of formulation/polymorph patents that can preserve exclusivity against “same API” generics
• Method-of-use claims that can support 35 U.S.C. § 271(a)/(b) arguments when labeling is contested or when off-label use is alleged in specialized litigation

Practical take: Enasidenib has the longest market history, which typically means:

• More generations of patent filings
• More survivable “last-man-standing” claims such as formulation/process
• Higher likelihood of earlier-filed base patents now closer to expiration, while secondary claims can extend practical barriers

What patents protect olutasidenib (Rezlidhia) and how strong is the estate?

Drug: Olutasidenib (IDH2 inhibitor; oral small molecule)
Primary patent estate focus:

• Composition-of-matter and IDH2 inhibitory activity claims
• Solvate/polymorph and drug product preparation claims
• Method-of-use for IDH2-mutant AML in defined relapse contexts

Practical take:

• Newer approvals tend to come with fewer “already-lapsed” base patents, so the risk profile for generic entry is often more sensitive to:
  • Whether challengers can design around composition claims or avoid triggering formulation/process claims
  • Whether Orange Book-listed patents include drug product and not only active ingredient coverage
  • Whether label protection is narrow or broad in AML relapse-line contexts

How many patents cover IDH2 inhibitors in the US Orange Book, and what types of patents are listed?

Orange Book coverage conceptually splits into:

• Active ingredient (composition-of-matter) coverage
• Drug product/formulation coverage (often key for non-bioequivalent generic designs)
• Use/relevant indications coverage (method-of-use or therapeutic method listings)
• Sometimes manufacturing or process-related patents where they are listed as “relevant”

Risk allocation from an IP strategy viewpoint:

• If Orange Book is dominated by drug product/polymorph patents, generic viability depends on finding a permitted alternative form and process.
• If dominated by method-of-use, generic launch may be blocked through Paragraph IV challenges targeting those listed patents unless the labels can be carved out cleanly.

When do IDH2 inhibitor patents expire, and what are the typical exclusivity timelines?

Key timelines that control market entry:

• Patent expiration (utility patents term based on earliest effective filing)
• Pediatric exclusivity (if granted; adds typically 6 months)
• Regulatory exclusivity (data exclusivity/marketing exclusivity by pathway, not always the dominant factor for these oncology small molecules)
• Orange Book-listed patent expiration by listing type (API vs formulation vs method)

Practical take for business planning:

• In IDH2, generic entry timing usually tracks the last Orange Book patent to expire for the specific listed indication(s), not the earliest base patent.
• For litigation and settlement leverage, the decisive factor is how many Orange Book patents remain live at the generic’s intended launch date.

What Paragraph IV challenges exist for enasidenib or olutasidenib?

What matters for outcomes:

• Whether a Paragraph IV filer targeted API patents vs formulation vs method-of-use listings
• Whether the case settled (and under what terms, such as design-around commitments, market entry dates, or non-infringement positions)
• Whether the court sustained a preliminary injunction (rare but value-creating if granted)
• Whether multiple patents were litigated with different claim construction outcomes

Outcome mapping (how it usually impacts market entry):

• If the generic wins early, launch can occur sooner, with potential price pressure on the incumbent.
• If only some patents fall, label and exclusivity carve-outs can delay entry while allowing partial competition.

What patent litigation affects IDH2 inhibitor market access in the US?

Litigation drivers:

• Composition-of-matter claim validity challenges (novelty/obviousness)
• Non-infringement arguments via structural design-around
• Infringement arguments framed around:
  • API molecular identity
  • Drug product form (polymorph/solvate)
  • Process steps (for process claims)
• Injunction or settlement-driven delay

Practical take:

• Enasidenib’s longer commercial history generally correlates with more litigated patent generations.
• Olutasidenib’s newer wave can shift risk to “next-tier” patents and formulation/process claims.

How do IDH2 inhibitor patent estates compare: enasidenib vs olutasidenib vs vorasidenib?

Comparison axes:

1. Patent age and remaining term
2. Breadth of composition-of-matter coverage
3. Presence and durability of formulation/polymorph patents
4. Degree of method-of-use labeling protection
5. Settlement record frequency (driven by number of live patents and how courts interpret claim scope)

Typical business pattern:

• Enasidenib often has deeper “stacking” history with multiple ancillary patents.
• Olutasidenib usually shows stronger remaining base and intermediate-term coverage at the time of approval.
• Vorasidenib’s dual targeting can shift landscape because some claims cover IDH1/IDH2 dual pharmacology and may diverge from IDH2-only challengers’ design spaces.

What formulation and manufacturing patents can block generic competition for IDH2 inhibitors?

For small molecule oncology inhibitors, the most common generic bottlenecks are:

• Polymorph/crystal form patents: alternative forms may be non-infringing or outside the claimed form.
• Solvates/hydrates patents: control bioavailability and stability; can be used to create product identity barriers.
• Particle size distribution and milling process: affects dissolution and can be claimed via drug product process.
• Manufacturing process claims: if the process is a patented synthesis route, a generic can face design-around requirements or process licensing.

Business implications:

• Even when composition claims are weak, formulation and process patents can still protect commercial exclusivity longer than API-only estates.

What method-of-use patents protect IDH2 inhibitors and how do they affect label carve-outs?

Method-of-use protection impacts:

• Whether a generic can launch with a carved label that avoids the protected patient population or regimen.
• Whether enforcement targets induced infringement for pharmacists/physicians under US law when prescribing the protected regimen.

Key practicalities:

• IDH2 inhibitors are biomarker-defined. Claim scopes often map to:
  • IDH2 mutation status
  • Specific relapse contexts
  • Combination vs monotherapy settings
• Carve-outs succeed when labeling can avoid protected indications without being practically obsolete.

What is the biosimilar risk for IDH2 inhibitors?

IDH2 inhibitors are small-molecule drugs. They are not biologics and thus are not subject to biosimilar pathways. Competition risk is primarily generic small molecule entry and, in some circumstances, authorized generics or follow-on formulations.

How does FDA regulatory status influence market timing and generic entry for IDH2 inhibitors?

Regulatory status affects:

• The number and identity of Orange Book-listed patents that must be certified.
• Whether the generic route uses ANDA (small molecule) with Paragraph IV certifications.
• Label protection and indicator scope, which directly affect design-around feasibility.

Practical take:

• For oncology small molecules, FDA labeling is the enforcement map. The narrower the label, the more carve-out options a challenger can use.

Which companies are most exposed to IDH2 patent barriers and where is generic risk concentrated?

Most exposed incumbent IP holders:

• Bristol Myers Squibb / Celgene (enasidenib)
• Blueprint Medicines (olutasidenib)
• Servier / Agios (via dual IDH1/IDH2 positioning for vorasidenib)

Most exposed generic challengers (business risk profile):

• Any ANDA filer targeting the same listed patents for the same indication(s) in the US.
• Filers choosing aggressive Paragraph IV strategies concentrate risk in:
  • Willingness to litigate multiple listed patents
  • Ability to prove non-infringement on formulation/polymorph or method-of-use claims

Settlement dynamics: how do licensing deals typically extend exclusivity for IDH2 drugs?

Common settlement structures in small molecule oncology include:

• “Launch date” covenants: authorized generic launch delayed to avoid losing key patents.
• Design-around obligations: the challenger commits to a formulation or process that avoids specific infringement theories.
• Cross-licenses in some cases where both sides have overlapping IP.
• Payment-for-delay risk can arise depending on terms, but commercially the key input is the effective entry date.

Business planning lens:

• The effective barrier is what the settlement allows, not just the earliest patent expiration.

What patent expiration and “last launch date” scenarios matter for market entry planning?

Scenario model used in market entry planning (structure):

• Determine earliest expiration of:
  • API-related patents (often first to expire)
  • formulation/polymorph patents (often last to expire)
  • method-of-use patents relevant to the approved indication
• Add any granted exclusivity extensions that apply to the listed drug
• Assess injunction risk: if a court stays enforcement or if a preliminary injunction is sought and denied, market timing shifts.

Practical take:

• For incumbents, formulation/method-of-use patents generally drive the latest entry scenario.
• For generics, the key is whether they can certify “not infringed” and prevail on the most meaningful remaining listings.

Key Takeaways

• IDH2 inhibitor competition is driven by a small set of marketed drugs: enasidenib and olutasidenib in IDH2-only positioning, with vorasidenib as dual-path for related but distinct competitive dynamics.
• Patent strategy and generic risk hinge on Orange Book listing composition: API patents set the baseline, while formulation/polymorph and method-of-use listings commonly control last-effective entry timing.
• Paragraph IV outcomes and settlements typically determine practical launch windows more than theoretical expiration dates.
• Because these are small molecules, the competitive threat is generic/ANDA and not biosimilars.

FAQs

1. Do IDH2 inhibitor generics need Paragraph IV certifications for both API and formulation patents?
2. Can a generic enasidenib or olutasidenib launch with a carved AML indication label to avoid method-of-use patents?
3. What product attributes (polymorph, solvate, particle size) most frequently determine infringement for IDH2 small molecules?
4. How do court claim-construction outcomes typically affect infringement findings in oncology small-molecule patent cases?
5. What settlement terms most influence the effective generic launch date for IDH2 inhibitors in the US?

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. (Accessed 2026-07-13).
2. FDA. Drugs@FDA Database. U.S. Food and Drug Administration. (Accessed 2026-07-13).